How Divi’s Laboratories Exceeded Expectations in FY25: A look into the Results I CompoundingAI

Vikas Rajput 2025-05-17

Overview: Divi’s Laboratories Delivers Strong FY25 Results

Divi’s Laboratories has delivered a robust close to FY25, surpassing expectations across revenue, margin, and profitability metrics.

With its Kakinada Unit III now operational and several high-potential growth levers underway, this performance is a validation of management’s consistent guidance and strategic capital deployment.

Let’s dissect how the actual results map to Divi’s stated plans and themes from earlier quarters.

Revenue Growth: As Guided, Delivered

What was guided:

Management consistently projected double-digit revenue growth through FY25.
Growth was to be led by strong Custom Synthesis momentum, recovery in generics despite pricing pressure, and stabilization in raw material costs.

What was delivered:

Q4 FY25 revenue: ₹2,585 crore → +12.2% YoY, +11.5% QoQ
FY25 full-year revenue: ₹9,360 crore → +19.31% YoY

This is ahead of the cautious optimism voiced in Q3 about base effect slowing YoY growth. Custom Synthesis (Q3 mix: 53%) seems to have delivered well, with volumes offsetting generic pricing headwinds. Management’s confidence in growth visibility has translated into results.

Margin Expansion: The Surprise Beat

What was guided:

Q3 saw concerns raised around margin sustainability at 32%, especially with higher regulatory costs, raw material volatility, and increased logistics burden (e.g., Red Sea disruptions).
No formal guidance was given, but commentary emphasized improving product mix and cost controls via backward integration.

What was delivered:

Q4 adjusted EBITDA margin: 34.27% (vs 32.04% in Q3 and 31.74% in Q4 FY24)
FY25 adjusted EBITDA margin: 31.71% (vs 28.11% in FY24)

This margin expansion directly addresses investor skepticism from previous calls. A few supporting factors stand out:

Material costs dropped from ₹1,021 crore in Q3 to ₹931 crore in Q4, despite a revenue rise.
Kakinada’s backward integration likely began contributing to cost efficiencies.
Forex gains in Q4 (₹10 crore vs. loss of ₹2 crore in Q4 FY24) helped PAT margins.
Other expenses were stable (+3% QoQ), indicating cost control amid higher revenue.

This is a clear validation of management’s multi-quarter messaging: margin pressures were transient and manageable with operational levers.

Profitability: Leverage in Motion

What was guided:

Operational leverage and lower tax regime (Section 115BAA) expected to improve PAT.
FY25 effective tax rate expected at 25% vs \~27–28% earlier.

What was delivered:

Q4 PAT: ₹662 crore → +23.05% YoY
FY25 PAT: ₹2,191 crore → +36.94% YoY
Effective tax rate FY25: 24.86%

PAT outpaced revenue growth due to margin lift and tax savings. EPS rose to ₹82.52 for FY25 vs ₹60.27 in FY24. The leverage from higher volumes and efficient capex utilization is visible.

Kakinada Unit III: From Plan to Performance

What was guided:

Kakinada Unit III Phase I to start in Jan 2025, ramp-up over next 6–8 months.
Total capex on project to exceed ₹1,300 crore, with operational costs in line with existing units.
No immediate EBITDA breakeven expected.

What was delivered:

₹755 crore of capex capitalized in FY25 out of total PPE addition of ₹1,118 crore.
CWIP still at ₹1,022 crore → indicates ongoing work on remaining phases.
Commentary reaffirms operational commencement and initial cost alignment.

The execution has followed the timeline closely, and early signs suggest that the unit has begun contributing to internal sourcing (starting materials), which may be one reason for lower input cost in Q4.

Custom Synthesis: Quiet but Likely Strong

What was guided:

Rising RFPs, new customer visits, and tailwinds from the US Biosecure Act.
Long-term manufacturing agreement (April 2025) with ₹650–700 crore capex commitment.
GLP-1 and contrast media as future drivers.

What was delivered:

No revenue split disclosed in Q4 results, but the margin and revenue beat point toward strong CS contribution.
Capex plans match past estimates , ₹1,438 crore invested in FY25, of which major part relates to Kakinada and possibly pilot plants for GLP-1.
Balance sheet shows healthy PPE and CWIP growth, supporting continued investment.

While the Q4 call didn’t split CS revenue, the growth suggests strong execution. Investors should continue watching GLP-1 scale-up and commercial traction in contrast media in FY26.

Working Capital: Receivables Warrant Monitoring

What was guided:

Inventory and receivables were stable till Q3. No red flags, but caution advised.

What was delivered:

Trade receivables rose 26.67% YoY (to ₹2,731 crore consolidated), outpacing revenue growth (19.3%).
Inventory growth at 1.63% YoY → very efficient.

Receivables increase is not alarming yet given strong cash flow and cash position (₹3,715 crore), but a further rise may invite scrutiny in FY26. Receivables stood at ₹2,366 crore in Q3 → a 15.4% jump in Q4.

Cash Flows & Dividend: Strength Maintained

Operating cash flow: ₹1,653 crore in FY25 → +31.09% YoY
Capex: ₹1,438 crore → aligns with ₹1,600 crore guidance
Dividend: ₹30/share recommended → in line with last year
Net cash position: Maintained; negligible debt

This reflects disciplined capital allocation, with strong OCF supporting heavy investment without taking on debt.

CFO Succession: Smooth Transition Ahead

Mr. L. Kishore Babu (CFO) is set to retire on August 1, 2025. Successor already named. This aligns with earlier announcements and is not expected to disrupt execution.

The Road Ahead: Platform Set for FY26

Key Watch Areas for FY26:

Ramp-up of Kakinada Unit III (full Phase I utilization by mid-year)
Revenue and margin impact from new manufacturing agreement
Expansion of GLP-1 and contrast media capabilities
Receivables trend stabilization
Contribution from new generics, with launches starting FY26 (e.g., Ticagrelor)

Final Takeaway: A Textbook Execution of Strategy

Divi’s FY25 results aren't just about strong numbers, they are about delivering on every key aspect discussed in earlier calls:

Guidance-backed growth ✔️
Margin resilience ✔️
Strategic capex conversion ✔️
Balance sheet discipline ✔️
Business model strengthening through Custom Synthesis ✔️

With a healthy order pipeline, operational leverage, new capacities, and margin tailwinds, Divi’s is entering FY26 with a full tank and a clear map.